Filing identity and reporting period
The supplied filing is Nemus Bioscience, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not a filing under the requested company name, Skye Bioscience, Inc. The filing describes a reverse merger completed October 31, 2014; Nemus became the accounting acquirer, so the comparative 2013 results principally reflect Nemus’s predecessor operations. Financial results are annual, not a standalone fourth quarter.
Business context
Nemus is an early-stage biopharmaceutical company developing cannabinoid-based therapies in partnership with the University of Mississippi (UM). Its candidates were in research or preclinical development, with no approved products, product sales, or established commercialization infrastructure. The former logistics business’s assets and liabilities were transferred to LGT immediately before the merger.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $227,500 | $0 |
| General and administrative expense | $2,504,161 | $120,403 |
| Total operating expenses | $2,731,661 | $120,403 |
| Net loss | $2,734,166 | $120,403 |
| Net cash used in operating activities | $1,755,208 | $0 |
Margins are not meaningful because the company had no revenue. Cash and cash equivalents were $207,330 at year-end 2014, versus none at year-end 2013. Current liabilities were $801,090 against current assets of $308,399; total liabilities were $801,895. The balance sheet reported a stockholders’ deficit of $453,548. No material borrowing or conventional debt balance is identified; reported long-term liabilities were $805.
Cash flow included $23,262 used in investing activities and $1,985,800 provided by financing activities. In January 2015, the company raised a further $724,989 through a common-stock sale. The auditor’s report states that recurring losses and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern.
Material changes and notable items
- Operating expenses rose to $2.73 million from $120,403, largely reflecting increased consulting and professional fees, public-company costs, and new research and development activity.
- R&D expense primarily reflected UM license fees for three cannabinoid programs. The company also recorded $466,200 of G&A expense for shares issued in exchange for releases of claims related to a prior entity.
- Three UM licenses were executed in September 2014, with upfront payments of $65,000 per license, annual fees of $25,000 per license, patent-cost reimbursements, and potential milestone and royalty payments.
- The company issued 4 million shares and warrants in 2014 financing transactions, completed the reverse merger, and reported 16 million shares outstanding at year-end. It reported 16,265,663 shares outstanding as of March 23, 2015.
Outlook, risks, and contingencies
Management expected continuing losses and significant R&D, laboratory, staffing, and public-company costs. The filing provides no quantified revenue or earnings guidance. It states that cash at year-end was inadequate to meet obligations within one year without additional funding; the risk discussion also says existing cash would not fund capital requirements for at least the next two months. Additional financing may be unavailable or dilutive, and the company could need to delay or reduce programs.
Principal risks include all candidates being early-stage; dependence on UM and other third parties; the need for DEA registrations and complex controlled-substance approvals; cannabis’s federal Schedule I status; lengthy FDA development and approval requirements; and competition, intellectual-property, manufacturing, reimbursement, and key-person risks. The company had not applied for or received its own DEA controlled-substance registrations. No current legal proceedings were reported. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer: this source is Nemus Bioscience, Inc., not Skye Bioscience, Inc., and covers the year ended December 31, 2014.
- Review the going-concern disclosures, cash runway assumptions, and subsequent financing; confirm whether additional capital was obtained and on what terms.
- Verify the status, costs, obligations, and termination provisions of UM licenses and the company’s progress toward DEA registrations and FDA-enabling studies.
- Assess dilution from issued shares, warrants, options, and any later financings; reconcile share counts across the merger and subsequent issuances.
- Examine the $466,200 share-based expense for releases of claims, related-party arrangements, and the company’s limited trading liquidity.